Preventing recurrence of high risk Neuroblastoma with Acyclic retinoid

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K18053
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55010:General surgery and pediatric surgery-related
• Research Institution: Shimane University
• Principal Investigator: Ishibashi Shuichi 島根大学, 医学部, 医科医員 (70834795)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: 神経芽細胞腫 / Acyclic retinoid / 分化誘導療法

Outline of Final Research Achievements

We examined the effect of acyclic retinoid (ACR) on cell viability and MYCN gene expression level using neuroblastoma (NB) cell lines. All-trans-retinoic acid (ATRA) and 13-cis-retinoic acid (13-cis RA) were used for comparison of ACR. Cell viability was significantly reduced by drug administration, but ACR was less effective than ATRA/13-cis RA. In addition, the expression level of MYCN gene was not observed in any of drugs. Based on recent reports, we also investigated the combination of differentiation therapy (ATRA+13-cis RA, 13-cis RA+ACR ATRA+ACR). In terms of cell viability, significant effects were observed in some cases with combination therapy rather than with single therapy.

Free Research Field

小児外科

Academic Significance and Societal Importance of the Research Achievements

神経芽細胞腫株を用いた今回の実験では、ACRの有効性は証明できなかった。また、分化誘導療法の併用によるcell viabilityの低下、MYCN遺伝子発現の低下を一部に確認できたが、その機序やタンパク質発現については不明であり、さらなる検証が必要である。これらの実験が発展し、高リスク群神経芽細胞腫の再発予防に対する分化誘導療法がより有効な治療法となることを期待したい。